Médicaments modificateurs de la maladie d’Alzheimer: implications pour la population canadienne

CMAJ. 2024 Jan 28;196(3):E110-E112. doi: 10.1503/cmaj.230595-f.
[Article in French]
No abstract available

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Canada
  • Humans

Substances

  • lecanemab
  • Antibodies, Monoclonal, Humanized